Step Therapy, Explained: Why Insurers Make You 'Fail First'

Roughly four in ten drug coverage policies in the United States use step therapy, according to an analysis of prescription protocols published on PubMed in November 2021. Most patients never notice, because most prescriptions in the U.S. (about 90%) are already for generics, which sit outside the rule entirely. The other 10% is where step therapy quietly decides what a doctor is allowed to prescribe first.

Step therapy, sometimes called "step protocol" or, more bluntly, "fail first," requires a patient to try a lower-cost drug before the health plan will cover the one their doctor originally prescribed. If the cheaper option doesn't work, the patient "steps up" to the next tier. Insurers frame it as basic cost control: many conditions can be treated by several similarly effective drugs at very different price points, and there's often no reliable way to predict in advance which one will work best for a given patient, according to healthinsurance.org's glossary entry on the practice. Starting with the cheaper, "step one" drug, typically a generic or preferred brand-name option, lowers costs for the insurer and, usually, the patient's copay too.

The harm shows up when the cheaper drug simply doesn't work for a particular patient. Because there's rarely a way to prove in advance that a step-one drug will fail, the patient has to actually take it, wait, and get worse before qualifying for the medication their doctor wanted to prescribe from the start. Switching insurers can reset the clock entirely: a patient who already worked through step therapy under one plan may have to start over under a new one that classifies "step one" and "step two" drugs differently, according to healthinsurance.org. At that point a doctor typically has to request a formal exception, sometimes called a step therapy override or coverage determination, to keep the treatment that was already working.

In dermatology, where step therapy protocols routinely apply to biologics for psoriasis, atopic dermatitis and hidradenitis suppurativa, the delay isn't abstract. Timely access to the right medication can dramatically affect outcomes, and step protocols not rooted in evidence-based medicine can prolong disease activity and complicate clinical decisions, the Biologic Coordinators of Dermatology wrote in a 2026 review of state step therapy laws.

That review is also the clearest evidence that the rules are shifting, unevenly, state by state. New Jersey's step therapy reform law took effect Jan. 1, 2026, placing guardrails on how insurers apply step protocols in state-regulated plans, including Medicaid. Rhode Island introduced legislation in 2026 to explicitly guarantee providers the right to request and secure exceptions when a step protocol is clinically inappropriate. New York's own reform, signed into law with the same Jan. 1, 2026 effective date, bars insurers from requiring a step therapy drug for longer than 30 days (or a shorter window if evidence-based guidelines call for it), caps "fail first" requirements at two drugs per condition, and blocks insurers from making a patient repeat step therapy within 365 days of a drug already being approved.

The protections have a hole built in, though: most only bind state-regulated insurance plans. Self-funded employer health plans, a large share of U.S. employer coverage, are typically governed by federal law instead and fall outside state step therapy reforms entirely. That's the gap the Safe Step Act, reintroduced in Congress, is aimed at closing. The bill would require ERISA plans to offer a clear, prompt exception process nationwide, standardizing protections that currently depend entirely on which state a patient happens to live in.

Until federal law catches up, the practical advice hasn't changed much: check whether a plan requires step therapy for a given drug before assuming coverage, keep records of what's already been tried and failed, and know that a doctor can request an exception; it just has to be requested. It's the same friction this site has tracked elsewhere in how insurers gate access to care, from why prior authorization still takes so long to which doctors get to skip it entirely. Step therapy is a narrower, drug-specific version of the same basic bargain: the insurer controls the order, and the patient absorbs the wait.